Physical Medicine & Rehabilitation, Pain Medicine · Augusta, GA
NPI
1104884246
Since 2006
Specialty
Physical Medicine & Rehabilitation, Pain Medicine
Code 2081P2900X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2922 Professional Pkwy, Ste A
Augusta, GA, 30907
Phone (706) 855-2767
Groups this clinician bills Medicare through
Medicare paid, 2024
$393K
11,457 services
Medicare patients, 2024
513
Average age 70
Drug cost, 2024
$799K
14,819 prescriptions
Company payments, 2025
$67.88
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John M Downey was code 99214 (office e&m - established), 3,248 times for 443 patients. In total John M Downey billed 11,457 services in 30 codes, and Medicare paid $393K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-01-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 3,248 | 443 | $77.93 | $253K |
| 20551 Musculoskeletal | Office | 2,629 | 270 | $27.35 | $72K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,528 | 293 | $0.73 | $1,109 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 1,526 | 293 | $0.50 | $763 |
| 97110 PT Treatment | Office | 1,077 | 63 | $16.10 | $17K |
| 97140 PT Treatment | Office | 533 | 62 | $13.38 | $7,129 |
| 99213 Office E&M - Established | Office | 366 | 126 | $53.38 | $20K |
| 20610 Joint Injection | Office | 161 | 49 | $36.83 | $5,929 |
| 20605 Joint Injection | Office | 118 | 45 | $29.64 | $3,497 |
| 97530 PT Treatment | Office | 67 | 29 | $23.56 | $1,579 |
| 97162 PT/OT Evaluation | Office | 62 | 51 | $63.56 | $3,941 |
| 95886 Electrical Nerve Conductivity | Office | 41 | 22 | $50.88 | $2,086 |
| 99202 Office E&M - New | Office | 30 | 30 | $45.40 | $1,362 |
| 95909 Electrical Nerve Conductivity | Office | 15 | 15 | $73.91 | $1,109 |
By year: 2022 $374K for 10,617 services; 2023 $422K for 11,400 services; 2024 $393K for 11,457 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80305 Drug Tests | 12 | 11 | $12.35 | $148 |
Medicare prescription drug claims, 2024
In 2024, the drug John M Downey prescribed most often to Medicare patients was Oxycodone Hcl, with 4,235 prescriptions and refills. In total John M Downey wrote 14,819 Medicare prescriptions that cost $799K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone Hcl Generic | 4,235 | 4,238 | 393 | $96K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 3,011 | 3,016 | 317 | $91K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,632 | 1,632 | 192 | $41K |
| Hydromorphone Hcl Generic | 585 | 585 | 70 | $12K |
| Gabapentin Generic | 520 | 671 | 90 | $7,517 |
| Morphine Sulfate Er Morphine Sulfate | 447 | 447 | 44 | $14K |
| Pregabalin Generic | 441 | 494 | 68 | $8,185 |
| Fentanyl Generic | 431 | 431 | 51 | $55K |
| Methadone Hcl Generic | 424 | 424 | 49 | $7,321 |
| Morphine Sulfate Generic | 398 | 398 | 64 | $11K |
| Tizanidine Hcl Generic | 327 | 419 | 68 | $3,130 |
| Tramadol Hcl Generic | 285 | 285 | 39 | $2,866 |
| Oxycontin Oxycodone Hcl | 190 | 190 | 16 | $137K |
| Meloxicam Generic | 171 | 221 | 45 | $439 |
| Cyclobenzaprine Hcl Generic | 127 | 150 | 31 | $1,064 |
Brand drugs: 875 claims; generic drugs: 13,944 claims; opioid claims: 11,990.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John M Downey $67.88 ($67.88 in general payments such as food, travel and fees) from 1 company. The largest payer was Boston Scientific Corporation with $67.88.
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation BSX | 3 | $67.88 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.